Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 410Cyclophosphamide 396Carboplatin 308Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 208fludarabine 193Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Histamine Antagonists × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡